Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Not the Usual Suspects: FDA Seeks New Advisors for Risk Communication Committee

This article was originally published in RPM Report

Executive Summary

The Food & Drug Administration is bringing a whole new constituency into the advisory committee process with the creation of an expert panel focused on improving the way the agency communicates risk information to the public. For industry, success will require even greater attention to foresee and address safety issues.

You may also be interested in...



FDA Advisory Committees on the Brink: More Meetings, Fewer Members

A year ago, Congress sent FDA two very clear, somewhat contradictory messages: Hold more advisory committee meetings, but without the use of many expert panelists used in the past. The result is a system that is stretched to the limits.

Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street

There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?

Leads & Contacts

Members of FDA Risk Communications Advisory Committee. Wyeth R&D senior execs meet with FDA drug review managers in September 2007. Oncologists, an ex-Congresswoman, and a former Bush Administration health policy advisor met with FDA senior managers (including Commissioner von Eschenbach) in October before FDA decidied to support the Centers for Medicare and Medicaid Services in its effort to restrict use of EPO for chemotherapy patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel